SHENZHEN, China, May 6, 2014 /PRNewswire/ -- Mindray Medical International Limited ("Mindray", NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today its selected unaudited financial results for the first quarter ended March 31, 2014.
Highlights for First Quarter 2014
"In the first quarter, the dynamics in various key markets continued to be challenging for our business. Nevertheless, we are pleased with our Western Europe performance, as well as our IVD reagent sales year-over-year increase," commented Mr. Li Xiting, Mindray's President and Co-Chief Executive Officer. "We are also excited about the launch of our first premium portable color ultrasound system, the M9, as well as the cellular analysis line, the CAL 8000, which demonstrate our capabilities of consistent innovation and our focus on making better healthcare solutions for our customers. Overall, management remains committed to delivering our financial goals for the year."
SUMMARY - First Quarter 2014
(in millions of US dollars, except per-share data)
| Three Months Ended | ||
March 31 | |||
2014 | 2013 | % chg | |
Net Revenues | 264.8 | 242.1 | 9.4% |
Net Revenues Generated in China | 115.8 | 111.3 | 4.0% |
Net Revenues Generated in International Markets | 148.9 | 130.8 | 13.9% |
Gross Profit | 146.0 | 139.1 | 5.0% |
Non-GAAP Gross Profit | 148.1 | 140.7 | 5.3% |
Operating Income | 31.3 | 39.0 | -19.8% |
Non-GAAP Operating Income | 42.3 | 46.3 | -8.7% |
EBITDA | 46.0 | 49.8 | -7.8% |
Net Income[1] | 35.6 | 57.4 | -37.9% |
Non-GAAP Net Income[1] | 46.1 | 64.6 | -28.7% |
Non-GAAP Net Income (ex tax benefit)[2] | 44.7 | 45.2 | -1.2% |
Diluted EPS | 0.30 | 0.48 | -36.7% |
Non-GAAP Diluted EPS | 0.39 | 0.53 | -27.2% |
[1] | For this press release, net income and non-GAAP net income refers to GAAP net income attributable to the Company and Non-GAAP net income attributable to the Company as stated in exhibit below, respectively. |
[2] | The non-GAAP net income (ex tax benefit) excludes the tax benefits of $19.4 million recognized in the first quarter of 2013 for the calendar years 2011 and 2012 and $1.4 million recognized in the first quarter of 2014 for the first quarter of calendar year 2014 in relation to the nationwide key software enterprise status. |
First Quarter 2014 Results
Net Revenues
Mindray reported net revenues of $264.8 million for the first quarter of 2014, a 9.4% increase from the first quarter of 2013.
Performance by Segment
Patient Monitoring and Life Support Products: Net revenues in this segment decreased 1.4% from the first quarter of 2013 to $98.0 million, contributing 37.0% to the total net revenues in this quarter.
In-Vitro Diagnostic Products: Net revenues in this segment increased 6.8% year-over-year to $73.0 million, contributing 27.6% to the total net revenues in this quarter. Reagents sales represented 38.1% of this segment's net revenues.
Medical Imaging Systems: Net revenues in this segment increased 27.1% from a year ago to $67.6 million, contributing 25.5% to the total net revenues in this quarter.
Others: Others net revenues increased 23.6% from the first quarter of 2013 to $26.2 million, contributing 9.9% to the total net revenues in this quarter. Others net revenues mainly include sales from the orthopedics business, service revenues from extended warranties, sales of accessories and repair-service revenues for the post-warranty period.
Gross Profit
First quarter 2014 gross profit was $146.0 million, a 5.0% increase from the first quarter of 2013. Non-GAAP gross profit was $148.1 million, a 5.3% increase from the first quarter of 2013. The gross margin was 55.1% compared to 57.4% in the first quarter of 2013 and 55.9% in the fourth quarter of 2013. Non-GAAP gross margin was 55.9% compared to 58.1% in the first quarter of 2013 and 56.5% in the fourth quarter of 2013.
Operating Expenses
Selling expenses for the first quarter of 2014 were $54.8 million, or 20.7% of the total net revenues, compared to 19.5% in the first quarter of 2013 and 16.7% in the fourth quarter of 2013. Non-GAAP selling expenses were $52.2 million, or 19.7% of the total net revenues, compared to 18.5% in the first quarter of 2013 and 16.1% in the fourth quarter of 2013.
General and administrative expenses for the first quarter of 2014 were $29.8 million, or 11.3% of the total net revenues, compared to 11.0% in the first quarter of 2013 and 13.5% in the fourth quarter of 2013. Non-GAAP general and administrative expenses were $24.6 million, or 9.3% of the total net revenues, compared to 10.0% in the first quarter of 2013 and 9.1% in the fourth quarter of 2013.
Research and development expenses for the first quarter of 2014 were $30.1 million, or 11.4% of the total net revenues, compared to 10.9% in the first quarter of 2013 and 11.1% in the fourth quarter of 2013. Non-GAAP research and development expenses were $29.1 million, or 11.0% of the total net revenues, compared to 10.5% in the first quarter of 2013 and 10.7% in the fourth quarter of 2013.
Total share-based compensation expenses for the first quarter of 2014, which were allocated to cost of revenues and related operating expenses, were $7.6 million, compared to $4.8 million in the first quarter of 2013 and $3.8 million in the fourth quarter of 2013.
Operating Income
Operating income in the first quarter of 2014 was $31.3 million, a 19.8% decrease from the first quarter of 2013. Non-GAAP operating income was $42.3 million, an 8.7% decrease from the first quarter of 2013. Operating margin was 11.8% compared to 16.1% in the first quarter of 2013 and 14.6% in the fourth quarter of 2013. Non-GAAP operating margin was 16.0% compared to 19.1% in the first quarter of 2013 and 20.6% in the fourth quarter of 2013.
Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA")
First quarter 2014 EBITDA decreased 7.8% year-over-year to $46.0 million.
Net Income
First quarter 2014 net income decreased 37.9% from a year ago to $35.6 million. Non-GAAP net income declined 28.7% from the first quarter of 2013 to $46.1 million. Net margin was 13.5%, compared to 23.7% in the first quarter of 2013 and 20.4% in the fourth quarter of 2013. Non-GAAP net margin was 17.4%, compared to 26.7% in the first quarter of 2013 and 20.0% in the fourth quarter of 2013. Excluding the tax benefits related to the nationwide key software enterprise status, first quarter 2014 non-GAAP net income decreased 1.2% year-over-year to $44.7 million and non-GAAP net margin was 16.9%, compared to 18.7% in the first quarter of 2013 and 17.8% in the fourth quarter of 2013. First quarter 2014 income tax expense was $4.5 million, compared to an income tax benefit of $12.9 million in the first quarter of 2013.
First quarter 2014 basic and diluted earnings per share were both $0.30, compared to $0.49 and $0.48 respectively in the first quarter of 2013. First quarter 2014 basic and diluted non-GAAP earnings per share were both $0.39, compared to $0.55 and $0.53 respectively in the first quarter of 2013. Shares used in the computation of diluted earnings per share for the first quarter of 2014 were approximately 118.3 million.
Other Selected Data
Accounts receivable turnover days were 69 days in the first quarter of 2014, compared to 66 days in the first quarter of 2013 and 50 days in the fourth quarter of 2013. Inventory turnover days were 114 days in the first quarter of 2014, compared to 103 days in the first quarter of 2013 and 79 days in the fourth quarter of 2013. Accounts payable turnover days were 78 days in the first quarter of 2014, compared to 59 days in the first quarter of 2013 and 54 days in the fourth quarter of 2013. Mindray calculates the above working capital days using the average of beginning and ending balances of the quarter.
As of March 31, 2014, the company had a total of $1.0 billion in cash and cash equivalents, and short-term investments as compared to $0.9 billion as of March 31, 2013 and $1.2 billion as of December 31, 2013. Net cash generated from operating activities and net cash outflow for capital expenditures for the first quarter of 2014 were $19.7 million and $27.9 million respectively.
As of March 31, 2014, the company had more than 7,900 employees, including those from the acquired businesses.
Business Outlook for Full Year 2014
The company continues to expect its full year 2014 net revenues to grow at least 15% over its full year 2013 net revenues. The company also continues to anticipate its full year 2014 non-GAAP net income to remain at a similar level to its full year 2013 non-GAAP net income. This guidance excludes the tax benefits related to the nationwide key software enterprise status and assumes a corporate income tax rate of 15% applicable to the Shenzhen subsidiary.
The company expects its capital expenditure for full year 2014 to be around $160 million.
The company's practice is to provide guidance on a full year basis only. This forecast reflects Mindray's current and preliminary views, which are subject to change.
Management Change
Separately, the company announced that Mr. Jie Liu has resigned from his Chief Operating Officer position for personal reasons, effective immediately. Mr. Wang Jianxin, Mindray's Chief Administrative Officer, will now be the Chief Operating Officer and will focus on research and development, China sales and marketing, manufacturing and supply chain management as well as some other operations. In addition, Mr. Minghe Cheng, Mindray's Co-Chief Executive Officer and Chief Strategic Officer, will oversee international sales and marketing and the North America operations, which were part of Mr. Liu's previous responsibilities.
"At this time, we are maintaining our financial guidance for 2014. We still expect Western Europe and some emerging countries to be the growth drivers, and the operating environment in China to gradually improve," commented Mr. Cheng Minghe, Mindray's Co-Chief Executive Officer and Chief Strategic Officer. "As we discussed earlier this year, we will continue to execute our investment strategy on strengthening our sales, marketing and distribution capabilities as well as product innovation, to further grow Mindray and improve our long-term position in the global marketplace. Last but not least, management will keep on exploring M&As and other collaboration opportunities."
Conference Call Information
Mindray's management will hold an earnings conference call at 8:00 AM on May 6, 2014 U.S. Eastern Time (8:00 PM on May 6, 2014 Beijing/Hong Kong Time).
Dial-in details for the earnings conference call are as follows:
International Toll Free:
United States: 866-519-4004
United Kingdom: 080-8234-6646
Hong Kong: 800-930-346
China: 800-819-0121
Local dial-in numbers:
United States: +1-845-675-0437
United Kingdom: +44-20-3059-8139
Hong Kong: +852-2475-0994
China: 400-620-8038
Passcode for all regions: Mindray
A replay of the conference call may be accessed by phone at the following numbers until May 20, 2014.
U.S. Toll Free: +1-855-452-5696
International: +1-646-254-3697
Passcode: 31694248
Additionally, a live and archived webcast of this conference call will be available on the Investor Relations section of Mindray's website at: http://ir.mindray.com/
Use of Non-GAAP Financial Measures
Mindray provides gross profit, selling expenses, general and administrative expenses, research and development expenses, operating income, net income and earnings per share on a non-GAAP basis that excludes share-based compensation expense and acquired intangible assets amortization expense, all net of related tax impact, as well as EBITDA to enable investors to better assess the company's operating performance for the first quarter of 2014. The non-GAAP measures described by the company are reconciled to the corresponding GAAP measure in the exhibit below titled "Reconciliations of non-GAAP results of operations measures to the nearest comparable GAAP measures".
The company has reported for the first quarter 2014 earnings on a non-GAAP basis. Each of the terms as used by the company is defined as follows:
The company computes its non-GAAP financial measures using the same consistent method from quarter to quarter. The company notes that these measures may not be calculated on the same basis of similar measures used by other companies. Readers are cautioned not to view non-GAAP results on a stand-alone basis or as a substitute for results under GAAP, or as being comparable to results reported or forecasted by other companies, and should refer to the reconciliation of GAAP results with non-GAAP results for the three months ended March 31, 2013 and 2014, respectively, in the attached financial information.
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including, without limitation, statements about Mindray's anticipated net revenues, non-GAAP net income and capital expenditure for 2014, our assumption of a corporate income tax rate of 15% applicable to the Shenzhen subsidiary, statements that overall, management remains committed to delivering our financial goals for 2014, that we still expect Western Europe and some emerging countries to be the growth drivers and the operating environment in China to gradually improve, that we will keep on executing our investment strategy on strengthening our sales, marketing and distribution capabilities as well as product innovation, to further grow Mindray and improve our long-term position in the global marketplace, that management will continue to explore M&As and other collaboration opportunities and other statements under "Business Outlook for Full Year 2014" are forward-looking statements. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors, including, without limitation, the growth and expected growth of the medical device market in China and internationally; applicable government policies and regulations; our ability to satisfy the requirements imposed by relevant regulatory bodies; market acceptance of our products; our expectations regarding demand for our products; our ability to expand our production, our sales and distribution network and other aspects of our operations; our ability to stay abreast of market trends and technological advances; our ability to effectively protect our intellectual property rights and not infringe on the intellectual property rights of others; our ability to settle disputes with our customers and suppliers; competition in the medical device industry in China and internationally; and general economic and business conditions in the countries in which we operate. For a discussion of other important factors that could adversely affect our business, financial condition, results of operations and prospects, see "Risk Factors" beginning on page 5 of our annual report on Form 20-F which was filed on April 28, 2014. Our results of operations for the first quarter of 2014 are not necessarily indicative of our operating results for any future periods. The financial information contained in this release should be read in conjunction with the consolidated financial statements and notes thereto included in our public filings with the Securities and Exchange Commission. Any projections in this release are based on limited information currently available to us, which is subject to change. Although such projections and the factors influencing them will likely change, we will not necessarily update the information. Such information speaks only as of the date of this release.
All references to "shares" are to our ordinary shares, which are divided into two classes, Class A and Class B. Each of our American Depositary Shares, which trade on the New York Stock Exchange, represents one Class A ordinary share.
About Mindray
We are a leading developer, manufacturer and marketer of medical devices worldwide. We maintain our global headquarters in Shenzhen, China, U.S. headquarters in Mahwah, New Jersey and multiple sales offices in major international markets. From our main manufacturing and engineering base in China, we supply through our worldwide distribution network a broad range of products across three primary business segments, namely patient monitoring and life support, in-vitro diagnostics, and medical imaging systems. For more information, please visit http://ir.mindray.com.
For investor and media inquiries, please contact:
In China:
Cathy Gao
Mindray Medical International Limited
Tel: +86-755-8188-8023
Email: cathy.gao@mindray.com
In the U.S:
Hoki Luk
Western Bridge, LLC
Tel: +1-646-808-9150
Email: hoki.luk@westernbridgegroup.com
Exhibit 1 | ||||
MINDRAY MEDICAL INTERNATIONAL LIMITED | ||||
CONDENSED CONSOLIDATED BALANCE SHEETS | ||||
(In thousands of US dollars) | ||||
As of December 31, 2013 | As of March 31, 2014 | |||
US$ | US$ | |||
(Note 1) | (unaudited) | |||
ASSETS | ||||
Current assets: | ||||
Cash and cash equivalents (Note 2) | 385,224 | 419,820 | ||
Restricted cash (Note 3) | 759 | 14,632 | ||
Short-term investments (Note 2) | 847,041 | 611,027 | ||
Accounts receivable, net | 220,228 | 182,226 | ||
Inventories | 138,808 | 158,613 | ||
Value added tax receivables | 10,225 | 14,208 | ||
Other receivables | 21,512 | 21,682 | ||
Prepayments and deposits | 14,310 | 17,340 | ||
Deferred tax assets,net | 9,585 | 10,429 | ||
Total current assets | 1,647,692 | 1,449,977 | ||
Restricted cash, non-current (Note 3) | 17,453 | 10,035 | ||
Other assets | 10,755 | 10,635 | ||
Accounts receivables, net, non-current | 1,389 | 573 | ||
Advances for purchase of plant and equipment | 18,919 | 20,544 | ||
Property, plant and equipment, net | 324,710 | 338,199 | ||
Land use rights, net | 59,463 | 58,875 | ||
Intangible assets, net | 181,077 | 176,446 | ||
Goodwill | 242,476 | 253,097 | ||
Total assets | 2,503,934 | 2,318,381 | ||
LIABILITIES AND EQUITY | ||||
Current liabilities: | ||||
Short-term bank loans | 260,000 | 210,000 | ||
Notes payable | 10,945 | 10,260 | ||
Accounts payable | 93,673 | 87,697 | ||
Advances from customers | 28,240 | 31,456 | ||
Salaries payable | 91,220 | 48,330 | ||
Other payables and current liabilities | 118,951 | 116,351 | ||
Purchase consideration payable | 20,457 | 29,412 | ||
Income taxes payable | 20,721 | 23,540 | ||
Other taxes payable | 12,832 | 7,233 | ||
Total current liabilities | 657,039 | 564,279 | ||
Long-term bank loans | 215,703 | 215,247 | ||
Other long-term liabilities | 7,222 | 9,090 | ||
Deferred tax liabilities, net | 45,812 | 47,672 | ||
Total liabilities | 925,776 | 836,288 | ||
Commitments and contingencies | ||||
Shareholders' equity: | ||||
Ordinary shares | 15 | 15 | ||
Additional paid-in capital | 521,617 | 451,410 | ||
Retained earnings | 865,676 | 842,603 | ||
Accumulated other comprehensive income | 150,432 | 136,128 | ||
Treasury stock at cost | (18,792) | (8,760) | ||
Total shareholders' equity | 1,518,948 | 1,421,396 | ||
Non-controlling interests | 59,210 | 60,697 | ||
Total equity | 1,578,158 | 1,482,093 | ||
Total liabilities and equity | 2,503,934 | 2,318,381 | ||
(1) Financial information is extracted from the audited financial statements included in the Company's 2013 annual report on Form 20-F. | ||||
(2) In respect of cash and cash equivalents and short-term investments, there is an aggregate compensating balance arrangement of $241,500 and $189,000 as of December 31, 2013 and March 31, 2014, respectively in relation to the drawings of certain bank loans. | ||||
(3) Restricted cash are mainly those purchase consideration in connection with our acquisitions being held on escrow accounts. | ||||
Exhibit 2 | ||||||
MINDRAY MEDICAL INTERNATIONAL LIMITED | ||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||
(In thousands of US dollars, except share and per share amounts) | ||||||
Three months ended March 31, | ||||||
2013 | 2014 | |||||
US$ | US$ | |||||
(unaudited) | (unaudited) | |||||
Net revenues | ||||||
- China | 111,332 | 115,828 | ||||
- International | 130,771 | 148,943 | ||||
Net revenues | 242,103 | 264,771 | ||||
Cost of revenues | (103,038) | (118,751) | ||||
Gross profit | 139,065 | 146,020 | ||||
Selling expenses | (47,157) | (54,796) | ||||
General and administrative expenses | (26,584) | (29,813) | ||||
Research and development expenses | (26,328) | (30,143) | ||||
Income from operations | 38,996 | 31,268 | ||||
Other income, net | 78 | 1,809 | ||||
Interest income | 7,687 | 10,779 | ||||
Interest expense | (972) | (2,395) | ||||
Income before income taxes and non-controlling interests | 45,789 | 41,461 | ||||
Income tax benefits (provision) | 12,934 | (4,500) | ||||
Net income | 58,723 | 36,961 | ||||
Less: Net income attributable to non-controlling interests | (1,299) | (1,323) | ||||
Net income attributable to the Company | 57,424 | 35,638 | ||||
Basic earnings per share | 0.49 | 0.30 | ||||
Diluted earnings per share | 0.48 | 0.30 | ||||
Shares used in the computation of: | ||||||
Basic earnings per share | 118,181,156 | 116,854,637 | ||||
Diluted earnings per share | 120,724,275 | 118,270,656 | ||||
Exhibit 3 | |||||
MINDRAY MEDICAL INTERNATIONAL LIMITED | |||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||
(In thousands of US dollars) | |||||
Three months ended March 31, | |||||
2013 | 2014 | ||||
US$ | US$ | ||||
(unaudited) | (unaudited) | ||||
Cash flow from operating activities: | |||||
Net income | 58,723 | 36,961 | |||
Adjustments to reconcile net income to net cash provided by operating activities | 15,310 | 27,864 | |||
Changes in assets and liabilities, net of effects of acquisitions | (31,643) | (45,159) | |||
Net cash provided by operating activities | 42,390 | 19,666 | |||
Cash flow from investing activities: | |||||
Acquisition cost of subsidiaries, net of cash received | (3,839) | (2,206) | |||
Capital expenditures | (20,042) | (27,875) | |||
Decrease (Increase) in restricted cash and restricted investment | 5,399 | (6,455) | |||
Proceeds from sale of short-term investments | 109,261 | 241,964 | |||
Increase in short-term investments and changes in other investing activities | (191,805) | (12,965) | |||
Net cash (used in) provided by investing activities | (101,026) | 192,463 | |||
Cash flow from financing activities: | |||||
Repayment of bank loan | - | (50,000) | |||
Proceeds from bank loans | 60,000 | - | |||
Dividend paid | (59,070) | (58,711) | |||
Proceeds from exercise of options | 6,754 | 345 | |||
Repurchase of ordinary American depositary shares | - | (68,029) | |||
Cash paid to acquire a non-controlling interest | (445) | ||||
Cash contribution from a non-controlling interest | - | 239 | |||
Net cash provided by (used in) financing activities | 7,684 | (176,601) | |||
Net (decrease) increase in cash and cash equivalents | (50,952) | 35,528 | |||
Cash and cash equivalents, beginning of period | 247,859 | 385,224 | |||
Effect of exchange rate changes on cash and cash equivalents | (1,163) | (932) | |||
Cash and cash equivalents, end of period | 195,744 | 419,820 | |||
Exhibit 4 | ||||||
MINDRAY MEDICAL INTERNATIONAL LIMITED | ||||||
RECONCILIATIONS OF NON-GAAP RESULTS OF OPERATIONS MEASURES TO THE NEAREST COMPARABLE GAAP MEASURES | ||||||
(In thousands of US dollars, except share and per share amounts) | ||||||
Three months ended March 31, | ||||||
2013 | 2014 | |||||
(unaudited) | (unaudited) | |||||
US$ | US$ | |||||
Non-GAAP net income attributable to the Company | 64,570 | 46,054 | ||||
Non-GAAP net margin | 26.7% | 17.4% | ||||
Amortization of acquired intangible assets | (2,602) | (3,447) | ||||
Deferred tax impact related to acquired intangible assets | 206 | 615 | ||||
Share-based compensation | (4,750) | (7,584) | ||||
GAAP net income attributable to the Company | 57,424 | 35,638 | ||||
GAAP net margin | 23.7% | 13.5% | ||||
Non-GAAP basic earnings per share | 0.55 | 0.39 | ||||
Non-GAAP diluted earnings per share | 0.53 | 0.39 | ||||
GAAP basic earnings per share | 0.49 | 0.30 | ||||
GAAP diluted earnings per share | 0.48 | 0.30 | ||||
Shares used in computation of: | ||||||
Basic earnings per share | 118,181,156 | 116,854,637 | ||||
Diluted earnings per share | 120,724,275 | 118,270,656 | ||||
Non-GAAP operating income | 46,348 | 42,299 | ||||
Non-GAAP operating margin | 19.1% | 16.0% | ||||
Amortization of acquired intangible assets | (2,602) | (3,447) | ||||
Share-based compensation | (4,750) | (7,584) | ||||
GAAP operating income | 38,996 | 31,268 | ||||
GAAP operating margin | 16.1% | 11.8% | ||||
Non-GAAP gross profit | 140,714 | 148,124 | ||||
Non-GAAP gross margin | 58.1% | 55.9% | ||||
Amortization of acquired intangible assets | (1,467) | (1,931) | ||||
Share-based compensation | (182) | (173) | ||||
GAAP gross profit | 139,065 | 146,020 | ||||
GAAP gross margin | 57.4% | 55.1% | ||||
Non-GAAP selling expenses | (44,906) | (52,174) | ||||
Non-GAAP as % of total net revenues | 18.5% | 19.7% | ||||
Amortization of acquired intangible assets | (1,135) | (1,516) | ||||
Share-based compensation | (1,116) | (1,106) | ||||
GAAP selling expenses | (47,157) | (54,796) | ||||
GAAP as % of total net revenues | 19.5% | 20.7% | ||||
Non-GAAP general and administrative expenses | (24,158) | (24,562) | ||||
Non-GAAP as % of total net revenues | 10.0% | 9.3% | ||||
Share-based compensation | (2,426) | (5,251) | ||||
GAAP general and administrative expenses | (26,584) | (29,813) | ||||
GAAP as % of total net revenues | 11.0% | 11.3% | ||||
Non-GAAP research and development expenses | (25,302) | (29,089) | ||||
Non-GAAP as % of total net revenues | 10.5% | 11.0% | ||||
Share-based compensation | (1,026) | (1,054) | ||||
GAAP research and development expenses | (26,328) | (30,143) | ||||
GAAP as % of total net revenues | 10.9% | 11.4% | ||||
Exhibit 5 | ||||||
MINDRAY MEDICAL INTERNATIONAL LIMITED | ||||||
RECONCILIATION OF GAAP NET INCOME TO EARNINGS BEFORE INTEREST, TAXES, DEPRECIATION AND AMORTIZATION | ||||||
(In thousands of US dollars) | ||||||
Three months ended March 31, | ||||||
2013 | 2014 | |||||
US$ | US$ | |||||
(unaudited) | (unaudited) | |||||
GAAP net income attributable to the Company | $ | 57,424 | 35,638 | |||
Interest income | (7,687) | (10,779) | ||||
Interest expense | 972 | 2,395 | ||||
Income tax (benefits) provision | (12,934) | 4,500 | ||||
Earnings before interest and taxes ("EBIT") | 37,775 | 31,754 | ||||
Depreciation | 7,776 | 8,628 | ||||
Amortization | 4,277 | 5,579 | ||||
Earnings before interest, taxes, depreciation, and amortization ("EBITDA") | 49,828 | 45,961 | ||||
![[Poster] Analytical Performance Experimentation assessment of the miLab™ MAL Malaria system for the detection of Plasmodium falciparum in clinical samples in Lagos, Nigeria](https://mma.prnasia.com/media2/2395917/Poster__Analytical_Performance_Experimentation_assessment_of_the_miLab__MAL_Malaria_system_for_the_d.jpg?p=medium600)